JP2023501789A5 - - Google Patents
Info
- Publication number
- JP2023501789A5 JP2023501789A5 JP2022525877A JP2022525877A JP2023501789A5 JP 2023501789 A5 JP2023501789 A5 JP 2023501789A5 JP 2022525877 A JP2022525877 A JP 2022525877A JP 2022525877 A JP2022525877 A JP 2022525877A JP 2023501789 A5 JP2023501789 A5 JP 2023501789A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- amorphous form
- further characterized
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025171004A JP2026016449A (ja) | 2019-11-08 | 2025-10-09 | 補体成分Ｃ５ａ受容体の非晶質形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962932644P | 2019-11-08 | 2019-11-08 | |
| US62/932,644 | 2019-11-08 | ||
| PCT/US2020/059280 WO2021092286A1 (en) | 2019-11-08 | 2020-11-06 | Amorphous form of a complement component c5a receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025171004A Division JP2026016449A (ja) | 2019-11-08 | 2025-10-09 | 補体成分Ｃ５ａ受容体の非晶質形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023501789A JP2023501789A (ja) | 2023-01-19 |
| JP2023501789A5 true JP2023501789A5 (https=) | 2023-11-10 |
Family
ID=75846408
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525877A Pending JP2023501789A (ja) | 2019-11-08 | 2020-11-06 | 補体成分Ｃ５ａ受容体の非晶質形態 |
| JP2025171004A Pending JP2026016449A (ja) | 2019-11-08 | 2025-10-09 | 補体成分Ｃ５ａ受容体の非晶質形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025171004A Pending JP2026016449A (ja) | 2019-11-08 | 2025-10-09 | 補体成分Ｃ５ａ受容体の非晶質形態 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11603356B2 (https=) |
| EP (1) | EP4054576A4 (https=) |
| JP (2) | JP2023501789A (https=) |
| KR (1) | KR20220098754A (https=) |
| CN (1) | CN114641288A (https=) |
| AU (1) | AU2020378397A1 (https=) |
| BR (1) | BR112022007489A2 (https=) |
| CA (1) | CA3155542A1 (https=) |
| CL (1) | CL2022001172A1 (https=) |
| IL (1) | IL292383A (https=) |
| MX (1) | MX2022005406A (https=) |
| WO (1) | WO2021092286A1 (https=) |
| ZA (1) | ZA202305624B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114867473A (zh) | 2019-11-08 | 2022-08-05 | 凯莫森特里克斯股份有限公司 | 补体成分c5a受体的盐形式 |
| US11603356B2 (en) | 2019-11-08 | 2023-03-14 | Chemocentryx, Inc. | Amorphous form of a complement component C5a receptor |
| WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
| EP4137133A1 (en) | 2021-08-19 | 2023-02-22 | Sandoz AG | Crystalline form of avacopan |
| WO2022263263A1 (en) | 2021-06-16 | 2022-12-22 | Sandoz Ag | Crystalline form of avacopan |
| US20250333381A1 (en) | 2024-04-26 | 2025-10-30 | Amgen Inc. | Solid state forms |
| US20260027049A1 (en) | 2024-07-23 | 2026-01-29 | Amgen Inc. | Avacopan formulations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4996467B2 (ja) * | 2004-09-27 | 2012-08-08 | アカディア ファーマシューティカルズ インコーポレイテッド | Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成 |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| RS54998B1 (sr) | 2008-12-22 | 2016-11-30 | Chemocentryx Inc | Antagonisti c5ar |
| RS56332B1 (sr) | 2010-06-24 | 2017-12-29 | Chemocentryx Inc | Antagonisti c5ar |
| DK3200791T3 (da) * | 2014-09-29 | 2020-05-25 | Chemocentryx Inc | Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister |
| CA3078732A1 (en) | 2017-10-31 | 2019-05-09 | Chemocentryx, Inc. | C5ar inhibitor reduction of urinary scd163 |
| US11191756B2 (en) | 2018-06-07 | 2021-12-07 | Chemocentryx, Inc. | Dosing and effect of C5a antagonist with ANCA-associated vasculitis |
| WO2020112961A1 (en) | 2018-11-30 | 2020-06-04 | Chemocentryx, Inc. | Capsule formulations |
| IL312955B1 (en) | 2019-03-11 | 2026-01-01 | Inflarx Gmbh | Fused piperidinyl bicyclic compounds and related compounds as C5a receptor modulators |
| CN114867473A (zh) | 2019-11-08 | 2022-08-05 | 凯莫森特里克斯股份有限公司 | 补体成分c5a受体的盐形式 |
| US11603356B2 (en) | 2019-11-08 | 2023-03-14 | Chemocentryx, Inc. | Amorphous form of a complement component C5a receptor |
| JP2022554019A (ja) | 2019-11-08 | 2022-12-27 | ケモセントリックス，インコーポレイティド | 補体成分Ｃ５ａ受容体の遊離塩基結晶形態 |
| WO2022078269A1 (zh) | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
-
2020
- 2020-11-06 US US17/091,001 patent/US11603356B2/en active Active
- 2020-11-06 CN CN202080077440.0A patent/CN114641288A/zh active Pending
- 2020-11-06 JP JP2022525877A patent/JP2023501789A/ja active Pending
- 2020-11-06 MX MX2022005406A patent/MX2022005406A/es unknown
- 2020-11-06 CA CA3155542A patent/CA3155542A1/en active Pending
- 2020-11-06 BR BR112022007489A patent/BR112022007489A2/pt unknown
- 2020-11-06 IL IL292383A patent/IL292383A/en unknown
- 2020-11-06 KR KR1020227018914A patent/KR20220098754A/ko not_active Ceased
- 2020-11-06 AU AU2020378397A patent/AU2020378397A1/en active Pending
- 2020-11-06 WO PCT/US2020/059280 patent/WO2021092286A1/en not_active Ceased
- 2020-11-06 EP EP20883775.7A patent/EP4054576A4/en active Pending
-
2022
- 2022-05-04 CL CL2022001172A patent/CL2022001172A1/es unknown
-
2023
- 2023-05-25 ZA ZA2023/05624A patent/ZA202305624B/en unknown
-
2025
- 2025-10-09 JP JP2025171004A patent/JP2026016449A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023501789A5 (https=) | ||
| JP2022554019A5 (https=) | ||
| HRP20171176T1 (hr) | C5ar antagonisti | |
| TWI344957B (en) | Chemical process and intermediates | |
| TW202204335A (zh) | Ｌｎｐ０２３之結晶形式 | |
| JP2010280715A (ja) | シナカルセト塩酸塩結晶フォームｉの調製方法 | |
| JP2022510304A5 (https=) | ||
| TWI613191B (zh) | 阿普斯特之新穎型式及其製造方法 | |
| JPS5829073B2 (ja) | タバコ製品及びその「ろ」過装置のための添加剤及びこの添加剤の製法 | |
| JP2020019813A5 (https=) | ||
| JP2017210488A5 (https=) | ||
| WO2021129467A1 (zh) | 一种bms-986165晶型及其制备方法和用途 | |
| JP2021091629A (ja) | Ｄ−アロース結晶及びその製造方法 | |
| JP2009527484A5 (https=) | ||
| CN110272724B (zh) | 一种碳基高导热定形相变材料的制备方法 | |
| JP4538842B2 (ja) | 新規ナテグリニド結晶 | |
| RU2022115355A (ru) | АМОРФНАЯ ФОРМА КОМПОНЕНТА КОМПЛЕМЕНТА РЕЦЕПТОРА C5a | |
| TW202033508A (zh) | 貝前列素-314d晶體及其製備方法 | |
| CN114671913A (zh) | 一种神经激肽-1拮抗剂的晶型及其制备方法 | |
| JP2010139696A5 (https=) | ||
| RU2009104346A (ru) | Ксинафоатная соль замещенного 5-оксазол-2-ил-хинолинового соединения | |
| JP2013503823A (ja) | （ｓ）‐ｎ‐メチル‐３‐（１‐ナフチルオキシ）‐３‐（２‐チエニル）プロピルアミン塩酸塩（デュロキセチン）の結晶化方法 | |
| CN104817557B (zh) | 一种盐酸莫西沙星的稳定晶型及其制备方法 | |
| IL300838A (en) | Co-crystals of an adenosine A2B receptor antagonist | |
| CN114364380A (zh) | (s)-2-((2s,3r)-1-氨基-3-羟基-1-氧代丁烷-2-基)-1-氧代-2,5-二氮杂螺[3.4]辛烷-5-甲酸叔丁酯的固体形式及其制备方法 |